As the world emerges from the COVID pandemic, diverse opportunities are opening up for Asian bioindustry, a fact not lost on global venture capital.

At BIO Asia—Taiwan 2022, keen insight from the **WI Harper Group, PwC, 8VC, Canaan Partners**, **Domain Associates, and O'Melveny** will be available in informative talks and engaging panel discussions, and a special session on Winning the Global Competition with Taiwanese DNA will be hosted by **Taiwania Capital Management Corp**.

Register now to get an advance sense of where biotech in Asia is headed, and take steps to position your organization in the Asian value chain today!

Hear from Experts

Session4: Exit Strategies for Early Stage New Drug Companies - Factors of Success

Join seasoned venture capitalists as they share experiences in funding early stage new drug companies and discuss exit strategies for diverse scenarios.

Distinguished Speakers From

pwc 資誠 · SENTI BIO · Canaan PARTNERS · DOMAIN ASSOCIATES · tlc BIOSCIENCES · O'Melveny · 8VC

Hear from Experts

Session9: Winning the Global Competition with Taiwanese DNA

Join a slate of promising Taiwanese biotech companies as they discuss their latest strategies to survive and thrive in a global competitive environment.

Distinguished Speakers From

台杉投資 TAIWANIA · WI HARPER GROUP SAN FRANCISCO · TAIPEI · BEIJING · AESOP · Health 2 Sync · AIxMed · 鉅怡智慧 FaceHeart

---

Who should attend?

- Venture capital and private equity seeking opportunities in Asian bioindustry.
- Value-based biotech startups looking to learn more about funding and exit strategies.
- Asian biotech companies exploring competitive advantages in a contested global environment.

REGISTER NOW! **LEARN MORE**

BIO Asia–Taiwan 2022 Secretariat
www.bioasiataiwan.com register@taiwanbio.org.tw +886-2-27836028